What is HC Wainwright’s Estimate for UNCY FY2024 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst E. Arce now anticipates that the company will earn ($0.11) per share for the year, up from their previous estimate of ($0.12). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.53 EPS.

Separately, Benchmark reissued a “speculative buy” rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research report on Friday, September 6th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Trading Up 2.7 %

Shares of UNCY stock opened at $0.46 on Monday. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82. The firm has a market capitalization of $47.75 million, a PE ratio of -0.47 and a beta of 2.29. The firm has a fifty day simple moving average of $0.43 and a two-hundred day simple moving average of $0.54.

Institutional Investors Weigh In On Unicycive Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Great Point Partners LLC purchased a new position in Unicycive Therapeutics in the third quarter worth $3,491,000. Walleye Capital LLC bought a new stake in Unicycive Therapeutics in the 3rd quarter worth $2,040,000. BVF Inc. IL increased its holdings in Unicycive Therapeutics by 70.5% during the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after purchasing an additional 1,493,462 shares during the period. Acuta Capital Partners LLC bought a new position in shares of Unicycive Therapeutics during the third quarter valued at approximately $807,000. Finally, Bleakley Financial Group LLC purchased a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $33,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.